Apellis Pharmaceuticals, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2025: USD -113.39 M

Apellis Pharmaceuticals, Inc. Common Stock Issued is USD -113.39 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -171.91% change year over year. Common stock issued is cash received from issuing new shares of the company’s common stock.
  • Apellis Pharmaceuticals, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 157.70 M, a -60.08% change year over year.
  • Apellis Pharmaceuticals, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 395.03 M, a -48.81% change year over year.
  • Apellis Pharmaceuticals, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 771.72 M, a 31,815.80% change year over year.
  • Apellis Pharmaceuticals, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 2.42 M, a -99.36% change year over year.
Key Data
Date Common Stock Issued Common Stock Repurchased Free Cash Flow Operating Cash Flow